Nanotechnological advances for the delivery of CNS therapeutics

Advanced Drug Delivery Reviews

Volumn 64, Issue 7, 2012, Pages 686-700

  Wong, Ho Lun ^a   Wu, Xiao Yu ^b   Bendayan, Reina ^b  

^a TEMPLE UNIVERSITY   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Blood brain barrier; Brain targeting; Central nervous system; Drug delivery; Nanomedicine; Nanotechnology

Indexed keywords

ACUTE ISCHEMIC STROKE; ALZHEIMER'S DISEASE; BLOOD-BRAIN BARRIER; BRAIN PARENCHYMA; BRAIN TISSUE; BRAIN TUMORS; CENTRAL NERVOUS SYSTEMS; DRUG DEVELOPMENT; IN-VITRO; NANO-EMULSIONS; NANO-SUSPENSIONS; NANOCARRIERS; NANOGELS; NANOMEDICINES; NEUROLOGICAL DISEASE; NEUROTOXICITY; NON-INVASIVE TREATMENT; POLYMERIC NANOPARTICLES; SOLID LIPID NANOPARTICLE (SLN); THERAPEUTIC AGENTS; TRANSCYTOSIS;

BLOOD; BRAIN; CEREBROSPINAL FLUID; DENDRIMERS; DRUG DELIVERY; FUNCTIONAL POLYMERS; LIPOSOMES; MEDICAL NANOTECHNOLOGY; MOLECULAR BIOLOGY; NANOPARTICLES; NANOTECHNOLOGY; NONINVASIVE MEDICAL PROCEDURES; PHOSPHOLIPIDS;

BRAIN MODELS;

ATAZANAVIR; BACLOFEN; CAMPTOTHECIN; CISPLATIN; DENDRIMER; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GADOLINIUM; INDINAVIR; LAMIVUDINE; LEUCINE ENKEPHALIN[2 DEXTRO ALANINE 6 ARGININE]; LIPOSOME; LOPERAMIDE; MACROGOL; MELATONIN; METHOTREXATE; NANOCARRIER; NANOPARTICLE; PACLITAXEL; PHENYTOIN; SMALL INTERFERING RNA; SOLID LIPID NANOPARTICLE; SUPEROXIDE DISMUTASE; SUPERPARAMAGNETIC IRON OXIDE; TEMOZOLOMIDE; UNINDEXED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; ZIDOVUDINE;

ALZHEIMER DISEASE; AREA UNDER THE CURVE; BLOOD BRAIN BARRIER; BLOOD CEREBROSPINAL FLUID BARRIER; BRAIN ISCHEMIA; BRAIN TUMOR; CENTRAL NERVOUS SYSTEM; CONTROLLED DRUG RELEASE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG PENETRATION; DRUG TARGETING; DRUG TRANSPORT; ENDOCYTOSIS; EPILEPSY; GLIOMA; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MICELLE; MICROBUBBLE; NANOEMULSION; NANOMEDICINE; NANOTECHNOLOGY; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; TRANSCYTOSIS; ULTRASOUND;

ANIMALS; BLOOD-BRAIN BARRIER; CENTRAL NERVOUS SYSTEM AGENTS; CENTRAL NERVOUS SYSTEM DISEASES; DRUG DELIVERY SYSTEMS; HUMANS; NANOPARTICLES; NANOTECHNOLOGY;

EID: 84859958800     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2011.10.007     Document Type: Review

References (211)

1. The Royal Society & The Royal Academy of Engineering, Chapter 4. Nanomanufacturing and the industrial application of nanotechnologies. Nanoscience and nanotechnologies: opportunities and uncertainties 2004, 25-34.
2. Neuwelt E.A., Bauer B., Fahlke C., Fricker G., Iadecola C., Janigro D., Leybaert L., Molnar Z., O'Donnell M.E., Povlishock J.T., Saunders N.R., Sharp F., Stanimirovic D., Watts R.J., Drewes L.R. Engaging neuroscience to advance translational research in brain barrier biology. Nat. Rev. Neurosci. 2011, 12:169-182.
3. Zlokovic B.V. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 2008, 57:178-201.
4. Pardridge W.M. The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2005, 2:3-14.
5. Weksler B.B., Subileau E.A., Perriere N., Charneau P., Holloway K., Leveque M., Tricoire-Leignel H., Nicotra A., Bourdoulous S., Turowski P., Male D.K., Roux F., Greenwood J., Romero I.A., Couraud P.O. Blood-brain barrier-specific properties of a human adult brain endothelial cell line. FASEB J. 2005, 19:1872-1874.
6. Abbott N.J. Astrocyte-endothelial interactions and blood-brain barrier permeability. J. Anat. 2002, 200:629-638.
7. Abbott N.J., Ronnback L., Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat. Rev. Neurosci. 2006, 7:41-53.
8. Hawkins B.T., Davis T.P. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol. Rev. 2005, 57:173-185.
9. Bendayan R., Lee G., Bendayan M. Functional expression and localization of p-glycoprotein at the blood brain barrier. Microsc. Res. Tech. 2002, 57:365-380.
10. Bendayan R., Ronaldson P.T., Gingras D., Bendayan M. In situ localization of p-glycoprotein (ABCB1) in human and rat brain. J. Histochem. Cytochem. 2006, 54:1159-1167.
11. Deeken J.F., Loscher W. The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin. Cancer Res. 2007, 13:1663-1674.
12. Loscher W., Potschka H. Drug resistance in brain diseases and the role of drug efflux transporters. Nat. Rev. Neurosci. 2005, 6:591-602.
13. Ronaldson P.T., Persidsky Y., Bendayan R. Regulation of ABC membrane transporters in glial cells: relevance to the pharmacotherapy of brain HIV-1 Infection. Glia 2008, 56:1711-1735.
14. Ohtsuki S., Terasaki T. Contribution of carrier-mediated transport systems to the blood-brain barrier as a supporting and protecting interface for the brain; importance for CNS drug discovery and development. Pharm. Res. 2007, 24:1745-1758.
15. Dallas S., Schlichter L., Bendayan R. Multidrug Resistance Protein (MRP) 4- and MRP 5-mediated efflux of 9-(2-phosphonylmethoxyethyl)adenine by microglia. J. Pharmacol. Exp. Ther. 2004, 309:1221-1229.
16. Kusuhara H., Sugiyama Y. Efflux transport systems for drugs at the blood-brain barrier and blood-cerebrospinal fluid barrier (Part 1). Drug Discov. Today 2001, 6:150-156.
17. Ronaldson P.T., Bendayan R. HIV-1 viral envelope glycoprotein Gp120 produces oxidative stress and regulates the functional expression of multidrug resistance protein-1 (MRP1) in glial cells. J. Neurochem. 2008, 106:1298-1313.
18. Zastre J.A., Chan G.N., Ronaldson R.T., Ramaswamy M., Couraud P.O., Romero I.A., Weksler B., Bendayan M., Bendayan R. Up-regulation of P-glycoprotein by HIV protease inhibitors in a human brain microvessel endothelial cell line. J. Neurosci. Res. 2009, 87:1023-1036.
19. Kusuhara H., Sugiyama Y. Efflux transport systems for drugs at the blood-brain barrier and blood-cerebrospinal fluid barrier (Part 2). Drug Discov. Today 2001, 6:206-212.
20. Dallas S., Miller D.S., Bendayan R. Multidrug resistance-associated proteins: expression and function in the central nervous system. Pharmacol. Rev. 2006, 58:140-161.
21. Spector R., Johanson C.E. The mammalian choroid plexus. Sci. Am. 1989, 261:68-74.
22. Groothuis D.R., Levy R.M. The entry of antiviral and antiretroviral drugs into the central nervous system. J. Neurovirol. 1997, 3:387-400.
23. Segal M.B. The choroid plexuses and the barriers between the blood and the cerebrospinal fluid. Cell. Mol. Neurobiol. 2000, 20:183-196.
24. Enting R.H., Hoetelmans R.M., Lange J.M., Burger D.M., Beijnen J.H., Portegies P. Antiretroviral drugs and the central nervous system. AIDS 1998, 12:1941-1955.
25. Davson H., Hollingsworth G., Segal M.B. The mechanism of drainage of the cerebrospinal fluid. Brain 1970, 93:665-678.
26. Saunders N.R., Habgood M.D., Dziegielewska K.M. Barrier mechanisms in the brain, I. adult brain. Clin. Exp. Pharmacol. Physiol. 1999, 26:11-19.
27. de Lange E.C. Potential role of ABC transporters as a detoxification system at the blood-CSF barrier. Adv. Drug Deliv. Rev. 2004, 56:1793-1809.
28. Garner C., Brown P.D. Two types of chloride channel in the apical membrane of rat choroid plexus epithelial cells. Brain Res. 1992, 591:137-145.
29. Kusuhara H., Sugiyama Y. Active efflux across the blood-brain barrier: role of the solute carrier family. NeuroRx 2005, 2:73-85.
30. Enerson B.E., Drewes L.R. The rat blood-brain barrier transcriptome. J. Cereb. Blood Flow Metab. 2006, 26:959-973.
31. Cohen B.E., Bangham A.D. Diffusion of small non-electrolytes across liposome membranes. Nature 1972, 236:173-174.
32. Camenisch G., Alsenz J., van de Waterbeemd H., Folkers G. Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs' lipophilicity and molecular weight. Eur. J. Pharm. Sci. 1998, 6:317-324.
33. van de Waterbeemd H., Camenisch G., Folkers G., Chretien J.R., Raevsky O.A. Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding descriptors. J. Drug Target. 1998, 6:151-165.
34. Pardridge W.M. Biopharmaceutical drug targeting to the brain. J. Drug Target. 2010, 18:157-167.
35. Kis O., Robillard K., Chan GN G.N., Bendayan R. The complexities of antiretroviral drug-drug interactions: role of ABC and SLC transporters. Trends Pharmacol. Sci. 2010, 31:22-35.
36. Ronaldson P.T., Ashraf T., Bendayan R. Regulation of multidrug resistance protein 1 by tumor necrosis factor alpha in cultured glial cells: involvement of nuclear factor-kappaB and C-jun N-terminal kinase signaling pathways. Mol. Pharmacol. 2010, 77:644-659.
37. Ronaldson P.T., Bendayan R. HIV-1 viral envelope glycoprotein Gp120 triggers an inflammatory response in cultured rat astrocytes and regulates the functional expression of P-glycoprotein. Mol. Pharmacol. 2006, 70:1087-1098.
38. Crone C. Facilitated transfer of glucose from blood into brain tissue. J. Physiol. 1965, 181:103-113.
39. Simionescu M., Gafencu A., Antohe F. Transcytosis of plasma macromolecules in endothelial cells: a cell biological survey. Microsc. Res. Tech. 2002, 57:269-288.
40. Voinea M., Dragomir E., Manduteanu I., Simionescu M. Binding and uptake of transferrin-bound liposomes targeted to transferrin receptors of endothelial cells. Vascul. Pharmacol. 2002, 39:13-20.
41. Prieto P., Blaauboer B.J., de Boer A.G., Boveri M., Cecchelli R., Clemedson C., Coecke S., Forsby A., Galla H.J., Garberg P., Greenwood J., Price A., Tähti H. Blood-brain barrier in vitro models and their application in toxicology. The report and recommendations of ECVAM Workshop 49, Altern. Lab. Anim. 2004, 32:37-50.
42. Wilhelm I., Fazakas C., Krizbai I.A. In vitro models of the blood-brain barrier. Acta Neurobiol. Exp. 2011, 71:113-128.
43. Garcel A., Martel S., Carrupt P.A., Doelker E., Delie F., In F. vitro blood brain barrier models as a screening tool for colloidal drug delivery systems and other nanosystems. Int. J. Biomed. Nanosci. Nanotechnol. 2010, 1:133-163.
44. Ribeiro M.M.B., Castanho M.A.R.B., Serrano I. In vitro blood-brain barrier models-latest advances and therapeutic applications in a chronological perspective. Mini Rev. Med. Chem. 2010, 10:263-271.
45. Chattopadhyay N., Zastre J., Wong H.L., Wu X.Y., Bendayan R. Solid lipid nanoparticles enhance the delivery of the HIV protease inhibitor, Atazanavir, by a human brain endothelial cell line. Pharm. Res. 2008, 25:2262-2271.
46. Wong H.L., Rauth A.M., Bendayan R., Wu X.Y. Combinational treatment with doxorubicin and GG918 (Elacridar) using polymer-lipid hybrid nanoparticles (PLN) and evaluation of strategies for multidrug-resistance reversal in human breast cancer cells. J. Control. Release 2006, 116:275-284.
47. Shuhendler A.J., Cheung R., Manias J., Connor A., Rauth A.M., Wu X.Y. A novel doxorubicin-mitomycin C co-encapsulated nanoparticle formulation exhibits anti-cancer synergy in multidrug resistant human breast cancer cells. Breast Cancer Res. Treat. 2009, 119:255-269.
48. Shuhendler A.J., Prasad P., Chan H.-K., Gordijo C.R., Saroushian B., Kolios M., Yu K., O'Brien P.J., Rauth A.M., Wu X.Y. Hybrid quantum dot-fatty ester stealth nanoparticles: toward clinically relevant in vivo optical imaging of deep tissue. ACS Nano 2011, 5:1958-1966.
49. Lee C.W., Lin E.H., Cheng J.Y., Wei P.K. Study of gold nanoparticles and live cells interactions by using planar evanescent wave excitation. J. Biomed. Opt. 2009, 14. 021005.
50. Kreuter J., Ramge P., Petrov V., Hamm S., Gelperina S.E., Engelhardt B., Alyautd R. Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles. Pharm. Res. 2003, 20:409-416.
51. Torchillin V.P. Drug targeting. Eur. J. Pharm. Sci. 2000, (Suppl 2):S81-S91.
52. Garcia-Alloza M., Bacskai B.J. Techniques for brain imaging in vivo. Neuromolecular Med. 2004, 6:65-78.
53. Strome E.M., Doudet D.J. Animal models of neurodegenerative disease: insights from in vivo imaging studies. Mol. Imaging Biol. 2007, 9:186-195.
54. Bhaskar S., Tian F., Stoeger T., Kreyling W., de la Fuente J.M., Grazú V., Borm P., Estrada G., Ntziachristos V., Razansky Daniel Multifunctional nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: perspectives on tracking and neuroimaging. Part. Fibre Toxicol. 2010, 7:3.
55. Veiseh O., Sun C., Fang C., Bhattarai N., Gunn J., Kievit F., Du K., Pullar B., Lee D., Ellenbogen R.G., Olson J., Zhang M. Specific targeting of brain tumors with an optical/magnetic resonance imaging nanoprobe across the blood-brain barrier. Cancer Res. 2009, 69:6200-6207.
56. Abulrob A., Brunette E., Slinn J., Baumann E., Stanimirovic D. Dynamic analysis of the blood-brain barrier disruption in experimental stroke using time domain in vivo fluorescence imaging. Mol. Imaging 2008, 7:248-262.
57. Härtig W., Paulke B.-R., Varga C., Seeger J., Harkany T., Kacza J. Electron microscopic analysis of nanoparticles delivering thioflavin-T after intrahippocampal injection in mouse: implications for targeting β-amyloid in Alzheimer's disease. Neurosci. Lett. 2003, 338:174-176.
58. Wong H.L., Chattopadhyay N., Wu X.Y., Bendayan R. Nanotechnology applications for improved delivery of antiretrovirals (ARVs) to the brain in HIV Infection. Adv. Drug Deliv. Rev. 2010, 62:503-517.
59. Yang H. Nanoparticle-mediated brain-specific drug delivery, imaging, and diagnosis. Pharm. Res. 2010, 27:1759-1771.
60. Invernici G., Cristini S., Alessandri G., Navone S.E., Canzi L., Tavian D., Redaelli C., Acerbi F., Parati E.A. Nanotechnology advances in brain tumors: the state of the art. Recent Pat. Anticancer Drug Discov. 2011, 6:58-69.
61. Wong H.L., Bendayan R., Rauth A.M., Li Y., Wu X.Y. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv. Drug Deliv. Rev. 2007, 59:491-504.
62. Kim D.H., Martin D.C. Sustained release of dexamethasone from hydrophilic matrices using PLGA nanoparticles for neural drug delivery. Biomaterials 2006, 27:3031-3037.
63. Alyaudtin R.N., Reichel A., Löbenberg R., Ramge P., Kreuter J., Begley D.J. Interaction of poly(butylcyanoacrylate) nanoparticles with the blood-brain barrier in vivo and in vitro. J. Drug Target. 2001, 9:209-221.
64. Rempe R., Cramer S., Huwel S., Galla H.J. Transport of Poly(n-butylcyano-acrylate) nanoparticles across the blood-brain barrier in vitro and their influence on barrier integrity. Biochem. Biophys. Res. Commun. 2011, 406:64-69.
65. Gao K., Jiang X. Influence of particle size on transport of methotrexate across blood-brain barrier by polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Int. J. Pharm. 2006, 310:213-219.
66. Alyautdin R., Gothier D., Petrov V., Kharkevich D., Kreuter J. Analgesic activity of the hexapeptide dalargin adsorbed on the surface of polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles. Eur. J. Pharm. Biopharm. 1995, 41:44-48.
67. Tian X.H., Lin X.N., Wei F., Feng W., Huang Z.C., Wang P., Ren L., Diao Y. Enhanced brain targeting of temozolomide in polysorbate-80 coated polybutylcyanoacrylate nanoparticles. Int. J. Nanomedicine 2011, 6:445-452.
68. Kim H.R., Andrieux K., Gil S., Taverna M., Chacun H., Desmaële D., Taran F., Georgin D., Couvreu P. Translocation of poly(ethylene glycol-co-hexadecyl) cyanoacrylate nanoparticles into rat brain endothelial cells: role of apolipoproteins in receptor-mediated endocytosis. Biomacromolecules 2007, 8:793-799.
69. Das D., Lin S. Double-coated poly(butylcynanoacrylate) nanoparticulate delivery systems for brain targeting of dalargin via oral administration. J. Pharm. Sci. 2005, 94:1343-1353.
70. Kuo Y.C., Chen H.H. Effect of nanoparticulate polybutylcyanoacrylate and methylmethacrylate-sulfopropylmethacrylate on the permeability of zidovudine and lamivudine across the in vitro blood-brain barrier. Int. J. Pharm. 2006, 327:160-169.
71. Dechy-Cabaret O., Martin-Vaca B., Bourissou D. Controlled ring-opening polymerization of lactide and glycolide. Chem. Rev. 2004, 104:6147-6176.
72. Gao X., Wu B., Zhang Q., Chen J., Zhu J., Zhang W., Rong Z., Chen H., Jiang X. Brain delivery of vasoactive intestinal peptide enhanced with the nanoparticles conjugated with wheat germ agglutinin following intranasal administration. J. Control. Release 2007, 121:156-167.
73. Zhang Q.Z., Zha L.S., Zhang Y., Jiang W.M., Lu W., Shi Z.Q., Jiang X.G., Fu S.K. The brain targeting efficiency following nasally applied mPEG-PLA nanoparticles in rats. J. Drug Target. 2006, 14:281-290.
74. Wong H.L., Li Y., Bendayan R., Rauth A.M., Wu X.Y. Solid-lipid nanoparticles for antitumor drug delivery. Nanotechnology for Cancer Therapeutics 2006, 714-776. CRC Press.
75. Huynh N.T., Passirani C., Saulnier P., Benoit J.P. Lipid nanocapsules: a new platform for nanomedicine. Int. J. Pharm. 2009, 379:201-209.
76. Muller R.H., Ruhl D., Runge S., Schulze-Forster K., Mehnert W. Cytotoxicity of solid lipid nanoparticles as a function of the lipid matrix and the surfactant. Pharm. Res. 1997, 14:458-462.
77. Fenart L., Casanova A., Dehouck B., Duhem C., Slupek S., Cecchelli R., Betbeder D. Evaluation of effect of charge and lipid coating on ability of 60-nm nanoparticles to cross an in vitro model of the blood-brain barrier. J. Pharmacol. Exp. Ther. 1999, 291:1017-1022.
78. Goppert T.M., Muller R.H. Polysorbate-stabilized solid lipid nanoparticles as colloidal carriers for intravenous targeting of drugs to the brain: comparison of plasma protein adsorption patterns. J. Drug Target. 2005, 13:179-187.
79. Kerwin B.A. Polysorbates 20 and 80 used in the formulation of protein biotherapeutics: structure and degradation pathways. J. Pharm. Sci. 2008, 97:2924-2935.
80. Zara G.P., Cavalli R., Fundaro A., Bargoni A., Caputo O., Gasco M.R. Pharmacokinetics of doxorubicin incorporated in solid lipid nanospheres (SLN). Pharm. Res. 1999, 40:281-286.
81. Yang S.C., Zhu J.B., Lu Y., Liang C.Z. Body distribution of camptothecin solid lipid nanoparticles after oral administration. Pharm. Res. 1999, 16:751-757.
82. Pandita D., Ahuja A., Lather V., Benjamin B., Dutta T., Velpandian T., Khar R.K. Development of lipid-based nanoparticles for enhancing the oral bioavailability of paclitaxel. AAPS PharmSci. Tech. 2011, 12:712-722.
83. Zara G.P., Cavalli R., Bargoni A., Fundaro A., Vighitto D., Gasco M.R. Intravenous administration to rabbits of non-stealth and stealth doxorubicin loaded solid lipid nanoparticles at increasing concentration of stealth agent: pharmacokinetics and distribution of doxorubicin in brain and in other tissues. J. Drug Target. 2002, 10:327-335.
84. Garcion E., Lamprecht A., Heurtault B., Paillard A., Aubert-Pouessel A., Denizot B., Menei P., Benoit J.P. A new generation of anticancer, drug-loaded, colloidal vectors reverses multidrug resistance in glioma and reduces tumor progression in rats. Mol. Cancer Ther. 2006, 5:1710-1722.
85. Priano L., Albani G., Brioschi A., Calderoni S., Lopiano L., Rizzone M., Cavalli R., Gasco M.R., Scaglione F., Fraschini F., Bergamasco B., Mauro A. Transdermal apomorphine permeation from microemulsions: a new treatment in Parkinson's disease. Mov. Disord. 2004, 19:937-942.
86. Priano L., Esposti D., Esposti R., Castagna G., De Medici C., Fraschini F., Gasco M.R., Mauro A. Solid lipid nanoparticles incorporating melatonin as new model for sustained oral and transdermal delivery systems. J. Nanosci. Nanotechnol. 2007, 7:3596-3601.
87. Priano L., Zara G.P., El-Assawy N., Cattaldo S., Muntoni E., Milano E., Serpe L., Musicanti C., Perot C., Gasco M.R., Miscio G., Mauro A. Baclofen-loaded solid lipid nanoparticles: preparation, electrophysiological assessment of efficacy, pharmacokinetic and tissue distribution in rats after intraperitoneal administration. Eur. J. Pharm. Biopharm. 2011, 79:135-141.
88. Wong H.L., Bendayan R., Rauth A.M., Wu X.Y. Development of solid lipid nanoparticles containing ionically complexed chemotherapeutic drugs and chemosensitizers. J. Pharm. Sci. 2004, 93:1993-2004.
89. Xue H.Y., Wong H.L. Tailoring nanostructured solid-lipid carriers for time-controlled intracellular siRNA kinetics to sustain RNAi-mediated chemosensitization. Biomaterials 2011, 32:2662-2672.
90. Xue H.Y., Wong H.L. Solid lipid-PEI hybrid nanocarrier: an integrated approach to provide extended, targeted and safer siRNA therapy of prostate cancer in an all-in-one manner. ACS Nano 2011, 5:7034-7034.
91. Brioschi A.M., Calderoni S., Zara G.P., Priano L., Gasco M.R., Mauro A. Solid lipid nanoparticles for brain tumors therapy: State of the art and novel challenges. Prog. Brain Res. 2009, 180:193-223. H.S. Sharma (Ed.).
92. Webb M.S., Rebstein P., Lamson W., Bally M.B. Liposomal drug delivery: recent patents and emerging opportunities. Recent Pat. Drug Deliv. Formul. 2007, 1:185-194.
93. Costantino L., Tosi G., Ruozi B., Bondioli L., Vandelli M.A., Forni F. Colloidal systems for CNS drug delivery. Prog. Brain Res. 2009, 180:35-69. H.S. Sharma (Ed.).
94. Zhang X., Xie J., Li S., Wang X., Hou X. The study on brain targeting of the amphotericin B liposomes. J. Drug Target. 2003, 11:117-122.
95. Anda T., Yamashita H., Fujita H.T., Yoshiharu T., Shibata S. Basic experiment of BBB permeability of cisplatin encapsulated in liposome by means of in vitro BBB. Drug Deliv. Syst. 1995, 10:425-430.
96. Kakinuma K., Tanaka R., Takahashi H., Sekihara Y., Watanabe M., Kuroki M. Drug delivery to the brain using thermosensitive liposome and local hyperthermia. Int. J. Hyperthermia 1996, 12:157-165.
97. Garg M., Asthana A., Agashe H.B., Agrawal G.P., Jain N.K. Stavudine-loaded mannosylated liposomes: in vitro anti-HIV-I activity, tissue distribution and pharmacokinetics. J. Pharm. Pharmacol. 2006, 58:605-616.
98. Mori N., Kurokouchi A., Osonoe K., Saitoh H., Ariga K., Suzuki K., Iwata Y. Liposome entrapped phenytoin locally suppresses amygdaloid epileptogenic focus created by db-cAMP/EDTA in rats. Brain Res. 1995, 703:184-190.
99. Fresta M., Puglisi G., Di Giacomo C., Russo A. Liposomes as in vivo carriers for citicoline: effects on rat cerebral post-ischaemic reperfusion. J. Pharm. Pharmacol. 1994, 46:974-981.
100. Soni V., Jain S.K., Kohli D.V. Potential of transferrin and transferrin conjugates of liposomes in drug delivery and targeting. Am. J. Drug Deliv. 2005, 3:155-170.
101. Désormeaux A., Bergeron M.G. Liposomes as drug delivery system: a strategic approach for the treatment of HIV infection. J. Drug Target. 1998, 6:1-15.
102. Bertrand N., Simard P., Leroux J.C. Serum-stable, long-circulating, pH-sensitive PEGylated liposomes. Methods Mol. Biol. 2010, 605:545-558.
103. Koukourakis M.I., Koukouraki S., Giatromanolaki A., Kakolyris S., Georgoulias V., Velidaki A., Archimandritis S., Karkavitsas N.N. High intratumoral accumulation of stealth liposomal doxorubicinin sarcomas-rationale for combination with radiotherapy. Acta Oncol. 2000, 39:207-211.
104. Kabanov A.V., Alakhov V.Y. Pluronic block copolymers in drug delivery: from micellar nanocontainers to biological response modifiers. Crit. Rev. Ther. Drug Carrier Syst. 2002, 19:1-72.
105. Zhang X., Alakhova D.Y., Batrakova E.V., Li S., Yang Z., Li Y., Kabanov A.V. Effect of Pluronic P85 on amino acid transport in bovine brain microvessel endothelial cells. J. Neuroimmune Pharmacol. 2009, 4:35-46.
106. Batrakova E.V., Li S., Alakhov V.Y., Miller D.W., Kabanov A.V. Optimal structure requirements for pluronic block copolymers in modifying P-glycoprotein drug efflux transporter activity in bovine brain microvessel endothelial cells. J. Pharmacol. Exp. Ther. 2003, 304:845-854.
107. Batrakova E.V., Li S., Miller D.W., Kabanov A.V. Pluronic P85 increases permeability of a broad spectrum of drugs in polarized BBMEC and Caco-2 cell monolayers. Pharm. Res. 1999, 16:1366-1372.
108. Kabanov A.V., Batrakova E.V., Alakhov V.Y. An essential relationship between ATP depletion and chemosensitizing activity of Pluronicreg block copolymers. J. Control. Release 2003, 91:75-81.
109. Svenson S. Dendrimers as versatile platform in drug delivery applications. Eur. J. Pharm. Biopharm. 2009, 71:445-462.
110. Dutta T., Jain N.K. Targeting potential and anti-HIV activity of lamivudine loaded mannosylated poly(propyleneimine) dendrimer. Biochim. Biophys. Acta 2007, 1770:681-686.
111. Dhanikula R.S., Argaw A., Bouchard J.F., Hildgen P. Methotrexate loaded polyether-copolyester dendrimers for the treatment of gliomas: enhanced intratumoral transport capability. Mol. Pharm. 2008, 5:105-116.
112. He H., Li Y., Jia X.R., Du J., Ying X., Lu W.L., Lou J.N., Wei Y. PEGylated poly(amidoamine) dendrimer-based dual-targeting carrier for treating brain tumors. Biomaterials 2011, 23:478-487.
113. Huang R.Q., Qu Y.H., Ke YH W.L., Zhu J.H., Pei Y.Y., Jiang C. Efficient gene delivery targeted to the brain using a transferring-conjugated polyethylene glycol-modified polyamidoamine dendrimer. FASEB J. 2007, 21:1117-1125.
114. Vinogradov S.V., Batrakova E.V., Kabanov A.V. Poly (ethylene glycol)-polyethyleneimine nanogel particles: novel drug delivery systems for antisense oligonucleotides. Colloids Surf. B Biointerfaces 1999, 16:291-304.
115. Vinogradov S.V., Batrakova E.V., Kabanov A.V. Nanogels for oligonucleotide delivery to the brain. Bioconjug. Chem. 2004, 15:50-60.
116. Sheetal S., Babbar A.K., Sharma R.K., Maitra A. Delivery of hydrophobised 5-fluorouracil derivative to brain tissue through intravenous route using surface modified nanogels. J. Drug Target. 2006, 14:87-95.
117. Desai A., Vyas T., Amiji M. Cytotoxicity and apoptosis enhancement in brain tumor cells upon coadministration of paclitaxel and ceramide in nanoemulsion formulations. J. Pharm. Sci. 2008, 97:2745-2756.
118. Kumar M., Misra A., Babbar A.K., Mishra A.K., Mishra P., Pathak K. Intranasal nanoemulsion based brain targeting drug delivery system of risperidone. Int. J. Pharm. 2008, 358:285-291.
119. Kumar M., Misra A., Mishra A.K., Mishra P., Pathak K. Mucoadhesive nanoemulsion-based intranasal drug delivery system of olanzapine for brain targeting. J. Drug Target. 2008, 16:806-814.
120. Vyas T.K., Shahiwala A., Amiji M.M. Improved oral bioavailability and brain transport of Saquinavir upon administration in novel nanoemulsion formulations. Int. J. Pharm. 2008, 347:93-101.
121. Shubar H.M., Dunay I.R., Lachenmaier S., Dathe M., Bushrab F.N., Mauludin R., Müller R.H., Fitzner R., Borner K., Liesenfeld O. The role of apolipoprotein-E in uptake of atovaquone into the brain in murine acute and reactivated toxoplasmosis. J. Drug Target. 2009, 17:257-267.
122. Dou H., Grotepas C.B., McMillan J.M., Destache C.J., Chaubal M., Werling J., Kipp J., Rabinow B., Gendelman H.E. Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of neuroAIDS. J. Immunol. 2009, 183:661-669.
123. González-Scarano F., Martín-García J. The neuropathogenesis of AIDS. Nat. Rev. Immunol. 2005, 5:69-81.
124. Bagasra O.E., Lavi L., Bobroski K., Khalili J.P., Pestaner R., Tawadros R., Pomerantz R.J. Cellular reservoirs of HIV-1 in the central nervous system of infected individuals: identification by the combination of in situ polymerase chain reaction and immunohistochemistry. AIDS 1996, 10:573-585.
125. Blankson J.N., Persaud D., Siliciano R.F. The challenge of viral reservoirs in HIV-1 infection. Ann. Rev. Med. 2002, 53:557-593.
126. Dalgliesh A.G., Beverley P.C.L., Clapman P.R., Crawford D.H., Greaves M.F., Weiss R.A. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 1984, 312:767-768.
127. Buckner J.C., Brown P.D., O'Neill B.P., Meyer F.B., Wetmore C.J., Uhm J.H. Central nervous system tumors. Mayo Clin. Proc. 2007, 82:1271-1286.
128. Fisher J.L., Schwartzbaum J.A., Wrensch M., Wiemels J.L. Epidemiology of brain tumors. Neurol. Clin. 2007, 25:867-890.
129. Lamprecht A., Benoit J.P. Etoposide nanocarriers suppress glioma cell growth by intracellular drug delivery and simultaneous P-glycoprotein inhibition. J. Control. Release 2006, 112:208-213.
130. Huang G., Zhang N., Bi X., Dou M. Solid lipid nanoparticles of temozolomide: potential reduction of cardial and nephric toxicity. Int. J. Pharm. 2008, 355:314-320.
131. Ferri C.P., Prince M., Brayne C., Brodaty H., Fratiglioni L., Ganguli M., Hall K., Hasegawa K., Hendrie H., Huang Y., Jorm A., Mathers C., Menezes P.R., Rimmer E., Scazufca M. Alzheimer's disease international, global prevalence of dementia: A Delphi consensus study. Lancet 2005, 366:2112-2117.
132. Cherney R.A., Atwood C.S., Xilinas M.E., Gray D.N., Jones W.D., McLean C.A., Barnham K.J., Volitakis I., Fraser F.W., Kim Y., Huang X., Goldstein L.E., Moir R.D., Lim J.T., Beyreuther K., Zheng H., Tanzi R.E., Masters C.L., Bush A.I. Treatment with a copper-zinc chelator markedly and rigidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 2001, 30:665-676.
133. Hartig W., Paulke B., Varga C., Seeger J., Harkany T., Kacza J. Electron microscopic analysis of nanoparticles delivering thioflavin-T after intrahippocampal injection in mouse: implications for targeting β -amyloid in Alzheimer's disease. Neurosci. Lett. 2003, 338:174-176.
134. Modi G., Pillay V., Choonara Y.E. Advances in the treatment of neurodegenerative disorders employing nanotechnology. Ann. N. Y. Acad. Sci. 2010, 1184:154-172.
135. Kogan M.J., Bastus N.G., Grillo-Bosch R.D., Araya E., Turiel A., Labarta A., Giralt E., Puntes V.F. Nanoparticle-mediated local and remote manipulation of protein aggregation. Nano Lett. 2006, 6:110-115.
136. Cui Z., Lockman P., Atwood R., Hsu C.H., Gupte A., Allen D.D., Mumper R.J. Novel d-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer's and other CNS diseases. Eur. J. Pharm. Biopharm. 2005, 59:263-272.
137. Liu G., Men P., Perry G., Smith M.A. Development of iron chelator-nanoparticle conjugates as potential therapeutic agents for Alzheimer disease. Prog. Brain Res. 2010, 180:97-108. H.S. Sharma (Ed.).
138. Yurek D. Nanoparticle gene therapy for Parkinson's disease. Nanotechwire.com (Accessed on 5.20.2011). http://nanotechwire.com/news.asp?nid=4393&ntid=183&pg=8.
139. Heart Disease and Stroke Statistics 2011 Update: a report from the American Heart Association. Circulation 2011, 123:e18-e209.
140. Saver J.L. Time is brain - Quantified. Stroke 2006, 37:263-266.
141. Goldstein L.B. Acute Ischemic Stroke Treatment in 2007. Circulation 2007, 116:1504-1514.
142. Marsh J.N., Senpan A., Hu G., Scott M.J., Gaffney P.J., Wickline S.A., Lanza G.M. Fibrin-targeted perfluorocarbon nanoparticles for targeted thrombolysis. Nanomedicine 2007, 2:533-543.
143. Reddy M.K., Labhasetwar V. Nanoparticle-mediated delivery of superoxide dismutase to the brain: an effective strategy to reduce ischemia-reperfusion injury. FASEB J. 2009, 23:1384-1395.
144. Marushima A., Suzuki K., Nagasaki Y., Yoshitomi T., Toh K., Tsurushima H., Hirayama A., Matsumura A. Newly synthesized radical-containing nanoparticles enhance neuroprotection after cerebral ischemia-reperfusion injury. Neurosurgery 2011, 68:1418-1426.
145. Takamiya M., Miyamoto Y., Yamashita T., Deguchi K., Ohta Y., Ikeda Y., Matsuura T., Abe K. Neurological and pathological improvements of cerebral infarction in mice with platinum nanoparticles. J. Neurosci. Res. 2011, 89:1125-1133.
146. de Boer A.G., van der Sandt I.C.J., Gaillard P.J. The role of drug transporters at the blood-brain barrier. Annu. Rev. Pharmacol. Toxicol. 2003, 43:629-656.
147. Huwyler J., Wu D., Pardridge W.M. Brain drug delivery of small molecules using immunoliposomes. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:14164-14169.
148. Huwyler J., Yan J., Pardridge W.M. Receptor mediated delivery of daunomycin using immunoliposomes: pharmacokinetics and tissue distribution in the rat. J. Pharmacol. Exp. Ther. 1997, 282:1541-1546.
149. Zhang Y., Calon F., Zhu C., Boado R., Pardridge W.M. Intravenous non-viral gene therapy causes normalization of striatal tyrosine hydroxylase and reversal of motor impairment in expertimental parkinsonism. Hum. Gene Ther. 2003, 14:1-12.
150. Pang Z., Lu W., Gao H., Hu K., Chen J., Zhang C., Gao X., Jiang X., Zhu C. Preparation and brain delivery property of biodegradable polymersomes conjugated with OX26. J. Control. Release 2008, 128:120-127.
151. Shi N., Zhang Y., Zhu C., Boado R.J., Pardridge W.M. Brain specific expression of an exogenous gene after i.v. administration. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:12754-12759.
152. Zhang Y., Lee H.J., Boado R.J., Pardridge W.M. Receptor-mediated delivery of an antisense gene to human brain cancer cells. J. Gene Med. 2002, 4:183-194.
153. Mamot C., Drummond D.C., Noble C.O., Kallab V., Guo Z., Hong K., Kirpotin D.B., Park J.W. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res. 2005, 65:11631-11638.
154. Wu D., Yang J., Pardridge W.M. Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor. J. Clin. Invest. 1997, 100:1804-1812.
155. Schwarze S.R., Ho A., Vocero-Akbani A., Dowdy S.F. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 1999, 285:1569-1572.
156. Liu L., Guo K., Lu J., Venkatraman S.S., Luo D., Moochhala S., Yang Y.Y. Biologically active core/shell nanoparticles self-assembled from cholesterol-terminated PEG-TAT for drug delivery across the blood-brain barrier. Biomaterials 2008, 29:1509-1517.
157. Kanazawa T., Taki H., Tanaka K., Takashima Y., Okada H. Cell-penetrating peptide-modified block copolymer micelles promote direct brain delivery via intranasal administration. Pharm. Res. 2011, 28:2130-2139.
158. Cai B., Lin Y., Xue X.H., Fang L., Wang N., Wu Z.Y. TAT-mediated delivery of neuroglobin protects against focal cerebral ischemia in mice. Exp. Neurol. 2011, 227:224-231.
159. Tosi G., Costantino L., Rivasi F., Ruozi B., Leo E., Vergoni A.V., Tacchi R., Bertolini A., Vandelli M.A., Forni F. Targeting the central nervous system: in vivo experiments with peptide-derivatized nanoparticles loaded with loperamide and rhodamine-123. J. Control. Release 2007, 122:1-9.
160. Vergoni A.V., Tosi G., Tacchi R., Vandelli M.A., Bertolini A., Costantino L. Nanoparticles as drug delivery agents specific for CNS: in vivo biodistribution. Nanomedicine 2009, 5:369-377.
161. Sabatier J.M., Vives E., Mabrouk K., Benjouad A., Rochat H., Duval A., Hue B., Bahraoui E. Evidence for neurotoxic activity of tat from human immunodeficiency virus type 1. J. Virol. 1991, 65:961-967.
162. Costantino L., Gandolfi F., Tosi G., Rivasi F., Vandelli M.A., Forni F. Peptide-derivatized biodegradable nanoparticles able to cross the blood brain barrier. J. Control. Release 2005, 108:84-96.
163. Demeule M., Currie J.-C., Bertrand Y., Christian C.H., Nguyen T., Gina A., Gabathuler R., Castaigne J.-P., Beliveau R. Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector Angiopep-2. J. Neurochem. 2008, 106:1534-1544.
164. Goppert T.M., Muller R.H. Polysorbate-stabilized solid lipid nanoparticles as colloidal carriers for intravenous targeting of drugs to the brain: comparison of plasma protein adsorption patterns. J. Drug Target. 2005, 13:179-187.
165. Kreuter J., Ramge P., Petrov V., Hamm S., Gelperina S.E., Engelhardt B., Alyautdin R., von Briesen H., Begley D.J. Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles. Pharm. Res. 2003, 20:409-416.
166. Michaelis K., Hoffmann M.M., Dreis S., Herbert E., Alyautdin R.N., Michaelis M., Kreuter J., Langer K. Covalent linkage of apolipoprotein E to albumin nanoparticles. J. Pharmacol. Exp. Ther. 2006, 317:1246-1253.
167. Lockman P.R., Oyewumi M.O., Koziara J.M., Roder K.E., Mumper R.J., Allen D.D. Brain uptake of thiamine-coated nanoparticles. J. Control. Release 2003, 93:271-282.
168. Eavarone D.A., Yu X., Bellamkonda R.V. Targeted drug delivery to C6 glioma by transferrin-coupled liposomes. J. Biomed. Mater. Res. 2000, 51:10-14.
169. Visser C.C., Stefanovich S., Voorwinden L.H., Gaillard P.J., Crommelin J.A., Danhof M., De Boer A.G. Validation of transferrin receptor for drug delivery to brain capillary endothelial cells in vitro. J. Drug Target. 2004, 12:145-150.
170. Saul J.M., Annapragada A., Natarajan J.V., Bellamkonda R.V. Controlled targeting of liposomal doxorubicin via the folate receptor in vitro. J. Control. Release 2003, 92:49-67.
171. Mora M., Sagrista M.L., Trombetta D., Bonina F.P., De Pasquale A., Sajia A. Design and characterization of liposomes containing long-chain N-AcylPEs for brain delivery: penetration of liposomes incorporating GM1 into the rat brain. Pharm. Res. 2002, 19:1430-1438.
172. Umezawa F., Eto Y. Liposome targeting to mouse brain: Mannose as a recognition marker. Biochem. Biophys. Res. Commun. 1988, 153:1038-1044.
173. Hu K., Shi Y., Jiang W., Han J., Huang S., Jiang X. Lactoferrin conjugated PEG-PLGA nanoparticles for brain delivery: preparation, characterization and efficacy in Parkinson's disease. Int. J. Pharm. 2011, 415:273-283.
174. Salama N.N., Kelly E.J., Bui T., Ho R.J. The impact of pharmacologic and genetic knockout of P-glycoprotein on nelfinavir levels in the brain and other tissues in mice. J. Pharm. Sci. 2005, 94:1216-1225.
175. Lee Y.J., Maeda J., Kusuhara H., Okauchi T., Inaji M., Nagai Y., Obayashi S., Nakao R., Suzuki K., Sugiyama Y., Suhara T. In vivo evaluation of P-glycoprotein function at the blood-brain barrier in non human primates using [11C] verapamil. J. Pharmacol. Exp. Ther. 2006, 316:647-653.
176. Gonatas N.K., Stieber A., Hickey W.F., Herbert S.H., Gonatas J.O. Endosomes and Golgi vesicles in adsorptive and fluid phase endocytosis. J. Cell Biol. 1984, 99:1379-1390.
177. Xiang J.J., Tang J.Q., Zhu S.G., Nie X.M., Lu H.B., Shen S.R., Li X.L., Tang K., Zhou M., Li G.Y. IONP-PLL: a novel non-viral vector for efficient gene delivery. J. Gene Med. 2003, 5:803-817.
178. Kumagai A.K., Eisenberg J.B., Pardridge W.M. Absorptive-mediated endocytosis of cationized albumin and a beta-endorphin-cationized albumin chimeric peptide by isolated brain capillaries model system of blood brain barrier transport. J. Biol. Chem. 1987, 262:15214-15219.
179. Lu W., Wan J., She Z., Jiang X. Bain delivery property and accelerated blood clearance of cationic albumin conjugated pegylated nanoparticle. J. Control. Release 2007, 118:38-53.
180. Lu W., Sun Q., Wan J., She Z., Jiang X. Cationic albumin-conjugated pegylated nanoparticles allow gene delivery into brain tumors via intravenous administration. Cancer Res. 2006, 66:11878-11887.
181. Lv H., Zhang S., Wang B., Cui S., Yan J. Toxicity of cationic lipids and cationic polymers in gene delivery. J. Control. Release 2006, 114:100-109.
182. Kumar V.V., Singh R.S., Chaudhuri A. Cationic transfection lipids in gene therapy: successes, set-backs, challenges and promises. Curr. Med. Chem. 2003, 10:1297-1306.
183. Qin L.J., Gu Y.T., Zhang H., Xue Y.X. Bradykinin-induced blood-tumor barrier opening is mediated by tumor necrosis factor-alpha. Neurosci. Lett. 2009, 450:172-175.
184. Sood R.R., Taheri S., Candelario-Jalil E., Estrada E.Y., Rosenberg G.A. Early beneficial effect of matrix metalloproteinase inhibition on blood-brain barrier permeability as measured by magnetic resonance imaging countered by impaired long-term recovery after stroke in rat brain. J. Cereb. Blood Flow Metab. 2008, 28:431-438.
185. Fleegal-DeMotta M.A., Doghu S., Banks W.A. Angiotensin II modulates BBB permeability via activation of the AT(1) receptor in brain endothelial cells. J. Cereb. Blood Flow Metab. 2009, 29:640-647.
186. van der Sandt I.C., Gaillard P.J., Voorwinden H.H., de Boer A.G., Breimer D.D. P-glycoprotein inhibition leads to enhanced disruptive effects by anti-microtubule cytostatics at the in vitro blood-brain barrier. Pharm. Res. 2001, 18:587-592.
187. Salahuddin T.S., Johansson B.B., Kalimo H., Johansson B.B., Olsson Y. Structural changes in the rat brain after carotid infusions of hyperosmolar solutions: a light microscopic and immunohistochemical study. Neuropathol. Appl. Neurobiol. 1988, 14:467-482.
188. Neuwelt E.A., Hill S.A., Frenkel E.P. Osmotic blood-brain barrier modification and combination chemotherapy: concurrent tumor regression in areas of barrier opening and progression in brain regions distant to barrier opening. Neurosurgery 1984, 15:362-366.
189. Fortin D., Gendron C., Boudrias M., Garant M.P. Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in the treatment of cerebral metastasis. Cancer 2007, 109:751-760.
190. Mistry A., Stolnik S., Illum L. Nanoparticles for direct nose-to-brain delivery of drugs. Int. J. Pharm. 2009, 379:146-157.
191. Illum L. Is nose-to-brain transport of drugs in man a reality?. J. Pharm. Pharmacol. 2004, 56:3-17.
192. Betbeder D., Sperandio S., Latapie J.P., de Nadai J., Etienne A., Zajac J.M., Frances B. Biovector (tm) nanoparticles improve antinociceptive efficacy of nasal morphine. Pharm. Res. 2000, 17:743-748.
193. Zhang Q., Jiang X., Jiang W., Lu W., Su L., Shi Z. Preparation of nimodipine loaded microemulsion for intranasal delivery and evaluation on the targeting efficiency to the brain. Int. J. Pharm. 2004, 275:85-96.
194. Gao X., Tao W., Lu W., Zhang Q., Zhang Y., Jiang X., Fu S. Lectin-conjugated PEGPLA nanoparticles: preparation and brain delivery after intranasal administration. Biomaterials 2006, 27:3482-3490.
195. Hynynen K., Mcdannold N., Sheikov N.A., Jolesz F.A., Vykhodtseva N. Local and reversible blood-brain barrier disruption by noninvasive focused ultrasound at frequencies suitable for trans-skull sonications. Neuroimage 2005, 24:12-20.
196. McDannold N., Vykhodtseva N., Raymond S., Jolesz F.A., Hynynen K. MRI-guided targeted blood-brain barrier disruption with focused ultrasound: histological findings in rabbits. Ultrasound Med. Biol. 2005, 31:1527-1537.
197. Kinoshita M., Mcdannold N., Jolesz F.A., Hynynen K. Noninvasive localized delivery of herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood-brain barrier disruption. Proc. Natl. Acad. Sci. U. S. A. 2006, 103(31):11719-11723.
198. Hynynen K. Ultrasound for drug and gene delivery to the brain. Adv. Drug Deliv. Rev. 2008, 60:1209-1217.
199. Vykhodtseva N., McDannold N., Hynynen K. Progress and problems in the application of focused ultrasound for blood-brain barrier disruption. Ultrasonics 2008, 48:279-296.
200. Raymond S.B., Treat L.H., Dewey J.D., McDannold N.J., Hynynen K., Bacskai B.J. Ultrasound enhanced delivery of molecular imaging and therapeutic agents in Alzheimer's disease mouse models. PLoS One 2008 May 14, 3(5):e2175.
201. Liu H.L., Hua M.Y., Chen P.Y., Chu P.C., Pan C.H., Yang H.W., Huang C.Y., Wang J.J., Yen T.C., Wei K.C. Blood-brain barrier disruption with focused ultrasound enhances delivery of chemotherapeutic drugs for glioblastoma treatment. Radiology 2010, 255:415-425.
202. Chen P.Y., Liu H.L., Hua M.Y., Yang H.W., Huang C.Y., Chu P.C., et al. Novel magnetic/ultrasound focusing system enhances nanoparticle drug delivery for glioma treatment. Neuro Oncol. 2010, 12:1050-1060.
203. Deng C.X., Huang X. Improved outcome of targeted delivery of chemotherapy drugs to the brain using a combined strategy of ultrasound, magnetic targeting and drug-loaded nanoparticles. Ther. Deliv. 2011, 2:137-141.
204. Hussain S.M., Javorina A.K., Schrand A.M., Duhart H.M., Ali S.F., Schlager J.J. The interaction of manganese nanoparticles with PC-12 cells induces dopamine depletion. Toxicol. Sci. 2006, 92:456-463.
205. Wang J., Rahman M.F., Duhart H.M., Newport G.D., Patterson T.A., Murdock R.C., Hussain S.M., Schlager J.J., Ali S.F. Expression changes of dopaminergic system-related genes in PC12 cells induced by manganese, silver, or copper nanoparticles. Neurotoxicology 2009, 30:926-933.
206. Pisanic T.R., Blackwell J.D., Shubayev V.I., Finones R.R., Jin S. Nanotoxicity of iron oxide nanoparticle internalization in growing neurons. Biomaterials 2007, 28:2572-2581.
207. Deng X., Luan Q., Chen W., Wang Y., Wu M., Zhang H., Jiao Z. Nanosized zinc oxide particles induce neural stem cell apoptosis. Nanotechnology 2009, 20:115101.
208. Long T.C., Saleh N., Tilton R.D., Lowry G.V., Veronesi B. Titanium dioxide (P25) produces reactive oxygen species in immortalized brain microglia (BV2): implications for nanoparticle neurotoxicity. Environ. Sci. Technol. 2006, 40:4346-4352.
209. Win-Shwe T.T., Yamamoto S., Ahmed S., Kakeyama M., Kobayashi T., Fujimaki H. Brain cytokine and chemokine mRNA expression in mice induced by intranasal instillation with ultrafine carbon black. Toxicol. Lett. 2006, 163:153-160.
210. Elder A., Gelein R., Silva V., Feikert T., Opanashuk L., Carter J., Potter R., Maynard A., Ito Y., Finkelstein J., Oberdorster G. Translocation of inhaled ultrafine manganese oxide particles to the central nervous system. Environ. Health Perspect. 2006, 114:1172-1178.
211. Oberdorster G., Sharp Z., Atudorei V., Elder A., Gelein R., Kreyling W., Cox C. Translocation of inhaled ultrafine particles to the brain. Inhal. Toxicol. 2004, 16:437-445.